XRAY · DENTSPLY SIRONA Inc.

Current Thesis

Dentsply Sirona's turnaround re-rating has failed its published price test: the 2026-09-11 close of $10.46 breached the $11 weekly-close condition, leaving sales stabilisation necessary for a renewed recovery case. The proposed narrative was that distribution expansion and operating improvement would support the company's return to growth. The August 29 research condition has now been met; it cannot remain a prospective floor.

The narrative is dead — this is an inference about the summer re-rating, dated by the 2026-09-11 weekly close below the previously published $11 threshold. It does not establish that the company's operating turnaround has permanently failed. A newly confirmed management appearance on 2026-09-15 provides an opportunity for an update, correcting the earlier description of an empty company calendar. Company event calendar

Bullish and bearish views on DENTSPLY SIRONA Inc.

The model's bull view on DENTSPLY SIRONA Inc. (XRAY), in brief: Annual guidance remains the anchor. On 2026-08-06, management reaffirmed fiscal 2026 sales of $3.5–3.6 billion and adjusted earnings per share (EPS) of $1.40–1.50. Tariff-refund benefits are excluded from that EPS outlook. Second-quarter results Cash generation improved with… The bear view: Revenue recovery remains unconfirmed. The 2026-08-06 release reported second-quarter sales of $898 million, down 4.1% year over year and 6.3% in constant currency, which removes exchange-rate effects. Second-quarter results Dental weakness spans business lines. Second-quarter… Both cases follow in full.

Bull Case

• Annual guidance remains the anchor. On 2026-08-06, management reaffirmed fiscal 2026 sales of $3.5–3.6 billion and adjusted earnings per share (EPS) of $1.40–1.50. Tariff-refund benefits are excluded from that EPS outlook. Second-quarter results
• Cash generation improved with assistance. Second-quarter 2026 operating cash flow was $99 million versus $48 million a year earlier; the August 6 release attributed the improvement primarily to approximately $44 million in tariff refunds and inventory and payable management. Second-quarter results
• Management has a dated forum. The September 3 announcement scheduled management's Baird Global Healthcare Conference presentation for 2026-09-15. The announcement establishes access to management, without promising updated financial results. Company announcement listing

Bear Case

• Revenue recovery remains unconfirmed. The 2026-08-06 release reported second-quarter sales of $898 million, down 4.1% year over year and 6.3% in constant currency, which removes exchange-rate effects. Second-quarter results
• Dental weakness spans business lines. Second-quarter 2026 Orthodontic and Implant Solutions sales fell 13.2% year over year; Connected Technology Solutions and Essential Dental Solutions also declined. August 6 results
• The published floor has failed. The adjusted market close was $10.46 on Friday, 2026-09-11, below the $11 weekly-close threshold published on 2026-08-29. That is an observed invalidation of the prior structure, irrespective of the forthcoming conference.

Setup & Price Structure

The 2026-09-11 adjusted daily-bar snapshot records a $10.46 close, a three-month price increase of 3.7%, and a 14-period relative strength index (RSI) of 40.6. It places the shares 28.7% below the 52-week high of $14.68. The positive three-month change does not reverse the observed breach of the published $11 threshold.

For a renewed recovery case, $11 is now a conditional recovery threshold: a weekly close above it would satisfy the price component of reassessment. The supplied September 11 snapshot contains no moving-average value or trading-volume series, so it cannot establish a replacement support area or widening participation.

Crowding is unmeasured in the September 13 evidence set: no current short-interest reading, retail-attention series or verified recent insider transaction is available. The dated September 15 conference establishes an upcoming attention event; it does not establish crowded ownership or an earnings release. Company event calendar

Catalyst Calendar (next 30 days)

The company calendar checked on 2026-09-13 does not confirm a third-quarter earnings date. The earlier November estimate therefore remains unconfirmed and is not presented as a scheduled catalyst. Company event calendar

Elapsed catalysts

• 2026-09-15 — Baird Global Healthcare Conference. Management is scheduled to present at 11:25 a.m. Eastern Daylight Time, according to the company's September 3 announcement and event calendar. Any disclosed change to annual guidance would directly affect the operating case; attendance alone would not resolve it. Company announcement listing, event calendar (passed 5d ago)

What Would Change Our Mind

The loss of the published recovery floor has already broken the price structure: a weekly close below $11 was the stated condition, and the 2026-09-11 close was $10.46. A subsequent recovery would be new evidence; it would not erase that dated failure.

A renewed turnaround case would require both a weekly close above $11 and a subsequent quarterly constant-currency sales decline no worse than the 6.3% reported for the second quarter on 2026-08-06, with annual guidance maintained. These are explicit reassessment conditions, not a forecast that recovery will occur. A reduction to the August 6 sales or adjusted EPS outlook would separately invalidate the guidance-supported operating case.

Correlation Notes

This remains a single-company turnaround assessment. The 2026-08-06 results showed Wellspect Healthcare growing 7.1% year over year while the dental segments contracted, demonstrating different operating trends within Dentsply Sirona itself. Second-quarter results

The September 11 price snapshot supplies no matched peer-return series. It therefore supports no measured correlation claim about dental peers, broader medical technology or an industry-wide recovery.